Answers are grounded in this paper and cite their sources.
Background: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) has tripled over the past 20 years. However, effective treatments for MASLD and MASH other than diet, exercise, pioglitazone, and tocopherol nicotinate are lacking. This single-arm study investigated the effects of pemafibrate treatment on lipid levels, liver function, diabetes, and weight-related changes in patients with steatotic liver disease.
No takes yet. Share an insight, caveat, or question.
Furuya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: